MARKET

YMTX

YMTX

Yumanity Therapeutics Inc
NASDAQ
1.580
+0.010
+0.64%
Opening 11:25 10/03 EDT
OPEN
1.580
PREV CLOSE
1.570
HIGH
1.620
LOW
1.569
VOLUME
5.89K
TURNOVER
7.57K
52 WEEK HIGH
10.56
52 WEEK LOW
0.9500
MARKET CAP
17.15M
P/E (TTM)
-0.4321
1D
5D
1M
3M
1Y
5Y
'Yumanity Therapeutics Patent App #20220298168 Published For "Compounds Useful In The Treatment Of Neurological Disorders" Target Alzheimer's' - U.S. Patent & Trademark Office
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20220298168&OS=20220298168&RS=20220
Benzinga · 4d ago
BRIEF-Yumanity Files Registration Statement On Form S-4 For Proposed Asset Sale To Janssen And Merger With Kineta
BRIEF-Yumanity Files Registration Statement On Form S-4 For Proposed Asset Sale To Janssen And Merger With Kineta
Reuters · 08/29 10:40
Yumanity Therapeutics Non-GAAP EPS of -$0.45, revenue of $1.66M
Yumanity Therapeutics press release (<span class=...
Seekingalpha · 08/04 21:16
-- Earnings Flash (YMTX) YUMANITY THERAPEUTICS Reports Q2 Revenue $1.66M
-- Earnings Flash (YMTX) YUMANITY THERAPEUTICS Reports Q2 Revenue $1.66M
MT Newswires · 08/04 16:31
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 06/09 11:26
Inside Kineta's plans after unveiling reverse merger deal
Kineta, a Seattle-based biotech, announced plans to go public through a reverse merger with Boston-based Yumanity. The deal could offer Kineta a major boost for its drug development pipeline.
American City Business Journals · 06/08 21:43
Yumanity Therapeutics to sell its pipeline, merge with Seattle biotech
The long-embattled neurodegenerative disease company will cease to exist after the deals are complete.
American City Business Journals · 06/07 17:48
Short Volatility Alert: Yumanity Therapeutics, Inc.
On Monday, shares of Yumanity Therapeutics, Inc. (NASDAQ: YMTX) experienced volatile short activity. After the activity, the stock price went up +40.14% to $1.99.  The overall sentiment for YMTX has been Bearish.
Benzinga · 06/07 15:37
More
About YMTX
Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company’s pipeline consists of programs focused on Parkinson’s disease, Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. The Company's technology platform enables the rapid screening for disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which results from an aberrant accumulation of misfolded proteins in the brain. The Company's product candidate includes YTX-7739, which is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease.

Webull offers kinds of Yumanity Therapeutics Inc stock information, including NASDAQ:YMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading YMTX stock methods without spending real money on the virtual paper trading platform.